Evidence Library
Filter by drug, type, year, and open access.
Showing 1–50 of 113 results
- Effect of adding cognitive behavioral therapy to quetiapine on suicide risk, depressive symptoms, and coping style in adult patients with mood disorders — Journal of Psychiatric Research (2026)• Drug: quetiapinePMID
- Effects of Long-Term Treatment with TV-46000 on Symptom Improvement Over Time in Stabilized Patients with Schizophrenia — CNS Drugs (2026)• Drug: risperidone-uzedyPMID
- The effect of switching antipsychotics to aripiprazole versus paliperidone on weight/cardiometabolic parameters: 18-month follow-up findings from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST) — European Neuropsychopharmacology (2026)• Drug: aripiprazolePMID
- Oral ketamine for the treatment of major depressive and bipolar disorder, a randomized controlled trial and meta-analysis — Journal of Affective Disorders (2026)• Drug: ketaminePMID
- Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial — JAMA Psychiatry (2026)• Drug: semaglutide-ozempicPMID
- Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial — JAMA Psychiatry (2026)• Drug: semaglutide-wegovyPMID
- Brexpiprazole for the treatment of co-occurring schizophrenia and substance use disorder: a multisite, randomized, controlled trial — Journal of Clinical Psychiatry (2025)• Drug: brexpiprazolePMID
- Assessing the metabolic impact of aripiprazole versus risperidone in the treatment of schizophrenia: a randomized double-blind controlled clinical trial — BMC Psychiatry (2025)• Drug: risperidoneOpen accessPMID
- Levomilnacipran, but not duloxetine, inhibits serotonin and norepinephrine reuptake throughout its therapeutic range — Journal of Clinical Psychiatry (2025)• Drug: levomilnacipranPMID
- A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release in Japanese patients with generalized anxiety disorder — Psychiatry and Clinical Neurosciences (2025)• Drug: venlafaxinePMID
- Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial — Journal of Clinical Psychiatry (2025)• Drug: lumateperonePMID
- Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial — American Journal of Psychiatry (2025)• Drug: lumateperonePMID
- Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release/duloxetine on cognition: A comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD) — Journal of Affective Disorders (2025)• Drug: duloxetinePMID
- Fixed-Dose Brexpiprazole and Sertraline Combination Therapy for the Treatment of Posttraumatic Stress Disorder: A Phase 3, Randomized Trial — Journal of Clinical Psychopharmacology (2025)• Drug: sertralinePMID
- Consistent differential effects of bupropion and mirtazapine in major depression — Journal of Affective Disorders (2025)• Drug: mirtazapinePMID
- Low-dose amitriptyline versus cognitive behavioral therapy for insomnia in patients with medical comorbidity: results of a randomized controlled multicenter non-inferiority trial — Sleep (2025)• Drug: amitriptylinePMID
- Assessing the metabolic impact of aripiprazole versus risperidone in the treatment of schizophrenia: a randomized double-blind controlled clinical trial — BMC Psychiatry (2025)• Drug: aripiprazoleOpen accessPMID
- Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release/duloxetine on cognition: A comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD) — Journal of Affective Disorders (2025)• Drug: aripiprazolePMID
- The behavioural effects of the serotonin 1A receptor agonist buspirone on cognition and emotional processing in healthy volunteers — Psychopharmacology (2025)• Drug: buspironePMID
- Zuranolone for the Treatment of Postpartum Depression — The American Journal of Psychiatry (2023)• Drug: zuranolonePMID
- Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials — The Lancet Neurology (2022)• Drug: daridorexantDOIPMID
- Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI) — Journal of Clinical Psychiatry (2022)• Drug: dextromethorphan-bupropionDOI
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — New England Journal of Medicine (2022)• Drug: tirzepatide-mounjaroDOI
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — New England Journal of Medicine (2022)• Drug: tirzepatide-zepboundDOI
- Phase III active- and placebo-controlled trial of vilazodone for major depressive disorder — Cureus (2021)• Drug: vilazodoneOpen accessDOIPMID
- Lumateperone monotherapy for bipolar depression: a randomized, placebo-controlled clinical trial — Journal of Clinical Psychiatry (2021)• Drug: lumateperoneDOIPMID
- Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy — Sleep (2021)• Drug: sodium-oxybate-extended-releaseDOI
- Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial — JAMA Psychiatry (2021)• Drug: zuranolonePMID
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — New England Journal of Medicine (2021)• Drug: semaglutide-ozempicDOI
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — New England Journal of Medicine (2021)• Drug: semaglutide-wegovyDOI
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2) — New England Journal of Medicine (2021)• Drug: tirzepatide-mounjaroDOI
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2) — New England Journal of Medicine (2021)• Drug: tirzepatide-zepboundDOI
- Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial — JAMA Psychiatry (2020)• Drug: lumateperoneDOIPMID
- Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy — Sleep (2020)• Drug: calcium-magnesium-potassium-and-sodium-oxybatesDOI
- Effect of olanzapine/samidorphan combination on weight gain — American Journal of Psychiatry (2020)• Drug: olanzapine-samidorphanDOI
- Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial — JAMA Network Open (2019)• Drug: lemborexantOpen accessDOIPMIDPMCID
- Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression — American Journal of Psychiatry (2019)• Drug: esketamineDOI
- A randomized study of solriamfetol for excessive sleepiness in narcolepsy — Annals of Neurology (2019)• Drug: solriamfetolDOIPMID
- Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial — American Journal of Respiratory and Critical Care Medicine (2019)• Drug: solriamfetolDOIPMID
- Safety and Efficacy of Lofexidine for Medically Managed Opioid Withdrawal: A Randomized Controlled Clinical Trial — Journal of Addiction Medicine (2019)• Drug: lofexidineOpen accessDOIPMIDPMCID
- Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans — New England Journal of Medicine (2018)• Drug: prazosinDOIPMID
- Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial — The Lancet (2018)• Drug: buprenorphine-naloxoneOpen accessDOIPMIDPMCID
- Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial — The Lancet (2018)• Drug: naltrexone-extended-releaseOpen accessDOIPMIDPMCID
- Cariprazine versus risperidone for predominant negative symptoms of schizophrenia — The Lancet (2017)• Drug: cariprazineDOIPMID
- Deutetrabenazine for tardive dyskinesia (AIM-TD phase 3 trial) — The Lancet Psychiatry (2017)• Drug: deutetrabenazineDOI
- KINECT 3: A phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia — American Journal of Psychiatry (2017)• Drug: valbenazineDOI
- A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal — Drug and Alcohol Dependence (2017)• Drug: lofexidineDOIPMID
- Liraglutide for Prediabetes/Obesity in Clozapine- or Olanzapine-Treated Schizophrenia Spectrum Disorder (RCT) — JAMA Psychiatry (2017)• Drug: semaglutide-ozempicOpen accessPMIDPMCID
- Liraglutide for Prediabetes/Obesity in Clozapine- or Olanzapine-Treated Schizophrenia Spectrum Disorder (RCT) — JAMA Psychiatry (2017)• Drug: semaglutide-wegovyOpen accessPMIDPMCID
- Liraglutide for Prediabetes/Obesity in Clozapine- or Olanzapine-Treated Schizophrenia Spectrum Disorder (RCT) — JAMA Psychiatry (2017)• Drug: tirzepatide-mounjaroOpen accessPMIDPMCID